论文部分内容阅读
B型金属β-内酰胺酶(metallo-β-lactamases,MBLs)抑制剂是目前在研的所有β-内酰胺酶抑制剂中较为热门的一类。本文结合国内外文献以及课题组先前的工作,简述了MBLs抑制剂的分类及其对β-内酰胺酶(β-lactamase)的抑制机制,并列举了一些目前在研的化合物,强调了开发MBLs抑制剂的紧迫性和在临床应用中的现实意义。随着研究的深入,MBLs抑制剂有望开发成为高效、低毒的抑制剂,在一定程度上解决临床上抗生素的细菌耐药问题,从而使临床上相关抗生素的使用发生革命性的变化。
B-type metallo-β-lactamases (MBLs) inhibitors are the most popular class of all β-lactamase inhibitors currently under investigation. In this paper, we summarize the classification of MBLs inhibitors and their inhibitory mechanism of β-lactamase based on the literature both at home and abroad as well as the previous work of the research group, and give some examples of the currently studied compounds, emphasizing the development The Urgency of MBLs Inhibitors and Its Practical Significance in Clinical Application. With the deepening of research, MBLs inhibitors are expected to develop into efficient, low toxicity inhibitors, to a certain extent, to solve the problem of bacterial resistance in clinical antibiotics, so that the clinical use of antibiotics has undergone a revolutionary change.